Fibrate Drugs Market size is expected to grow at a CAGR of 5% during the forecast period and the market size is expected to reach nearly US$ 4 Bn. by 2029. The report includes an analysis of the impact of COVID-19 lockdown on the revenue of market leaders, followers, and disruptors. Since the lockdown was implemented differently in various regions and countries; the impact of the same is also seen differently by regions and segments. The report has covered the current short-term and long-term impact on the market, and it would help the decision-makers to prepare the outline and strategies for companies by region.To know about the Research Methodology :- Request Free Sample Report Fibrate Drugs Definition: Fibrate drugs are administrated by the patients to improve the lipid and cholesterol levels in the blood. The fibrate containing medicines are particularly preferred by doctors to increase the levels of triglycerides in the body.
Fibrate Drugs Market Dynamics:
Cardiovascular diseases remain the biggest cause of death worldwide. In 2022, nearly 523 million populations are suffering from Cardio Vascular Disorders (CVDs) and died. The distributors and retailers of the fibrate drugs have vast growth opportunities in the ruler i.e., low-income countries of the world. From the ongoing statistical analysis for the fibrate drugs market, it is estimated that 42% of the population deaths occur due to Gastrointestinal Tract Disorders in Low-income countries and only 4% from high-income countries. Due to alcohol consumption, the peoples are suffering from fatty acids and cholesterol disorders. Hence the fibrates have a high demand in the urban areas and it is expected to have future opportunities in the global market.Fibrate Drugs Market Segment Analysis:
The report groups the Global Fibrate Drugs Market in different segments By Drug Type, Distribution Channel, and Region to forecast the revenues and analyze the market share of each segment over the forecast period. Based on Drug Type, the Global Fibrate Drugs Market is segmented into Clofibrate, Fenofibrates, Fenofibric Acids and Gemfibrozil. The Fenofibrates segment was dominant in 2022 and is expected to command a market share of xx% by 2029. Varieties of clinical trials have demonstrated that fenofibrate trigger elevated levels of cholesterol, and apolipoprotein. The observations of fenofibrate in healthy volunteers are resulting in steady-state maintenance of cholesterol and fatty acids for a 6-8 month period. Clinical trials have proved that fenofibrate decreases the plasma levels of lipoproteins by 7% to 23% it also reduces fibrinogen and lowers the levels of serum uric acid. This explains that the fenofibrate segment commanded the largest share of xx% in the global market. As well, large-scale production of fenofibrate in North America and Europe drives the global market in these regions. Abbott dominates the market and has large revenues of branded fenofibrate as well the products available for almost a next decade. The production of brand formulations of Abbott and many other market players imposes an annual cost of approximately US $ 700 million them which makes a positive impact on the healthcare system. In terms of end-user, the global fibrate drugs market can be divided into hospitals pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment commands the global fibrate drugs market & shares the xx% of revenue in the total market. Online pharmacies provide primary care for patients all over the world. E-prescribing interoperability solution provides the drug facilities in ambulatory surgical centers and saves the records accordingly. Hospital pharmacies solutions share information in different departments in and outside the hospitals. Monitoring the effect of medicines on the patients by all members of the healthcare team is driving the global fibrate drugs market.Fibrate Drugs Market Regional Insights:
North America is expected to command the largest market share of xx% by 2029. In North American countries, 13 million populations require fibrate drug therapy to meet the low-density lipoproteins goals set by the National Cholesterol Education Program. The major factor that drives the global market in this region is coronary heart disease the major death cause. The detection of CHD, as well as elevated serum cholesterol levels in individuals, embraces the global fibrate drugs market. Results from a 2022 study, 12.7 million adults need lipid-lowering drugs to maintain the low levels of cholesterol and lipoproteins which helps to extend the lifespan. Lifestyle-related disorders and the government's efforts to make improvements in the healthcare infrastructure are fuelling the growth of the global fibrate drugs market. The objective of the report is to present a comprehensive analysis of the Global Fibrate Drugs Market to the stakeholders in the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Global Fibrate Drugs Market dynamics, structure by analyzing the market segments and projects the Global Fibrate Drugs Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Fibrate Drugs Market make the report investor’s guide.Fibrate Drugs Market Scope: Inquire before buying
Fibrate Drugs Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 2.84 Bn. Forecast Period 2023 to 2029 CAGR: 5 % Market Size in 2029: US $ 4 Bn. Segments Covered: by Distribution Channel Hospitals Pharmacies Retail Pharmacies Online Pharmacies by Drug Type Clofibrate Fenofibrates Fenofibric Acids Gemfibrozil Global Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Fibrate Drugs Market Key Players
1. Teva Pharmaceutical Industries 2. Pfizer Inc. 3. Mylan N.V. 4. Sanofi SA 5. Novartis AG 6. GlaxoSmithKline plc 7. Sun Pharmaceutical Industries, Inc. 8. Macleods Pharmaceuticals Limited 9. Aurobindo Pharma 10.Abbott 11.Lupin 12.Zydus Candila 13.Hetero Drugs 14.Dr. Reddy’s Laboratories 15.Torrent Pharmaceuticals Frequently Asked Questions: 1. Which region has the largest share in Global Fibrate Drugs Market? Ans: North America region held the highest share in 2022. 2. What is the growth rate of Global Fibrate Drugs Market? Ans: The Global Market is growing at a CAGR of 5% during forecasting period 2023-2029. 3. What is scope of the Global Market report? Ans: Global Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Fibrate Drugs Market? Ans: The important key players in the Global Market are – Teva Pharmaceutical Industries, Pfizer Inc., Mylan N.V., Sanofi SA, Novartis AG, GlaxoSmithKline plc, Sun Pharmaceutical Industries, Inc., Macleods Pharmaceuticals Limited, Aurobindo Pharma, Abbott, Lupin, Zydus Candila, Hetero Drugs, Dr. Reddy’s Laboratories, and Torrent Pharmaceuticals 5. What is the study period of this Market? Ans: The Global Fibrate Drugs Market is studied from 2022 to 2029.
1. Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Fibrate Drugss Market Size, by Market Value (US$ Mn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2022 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Fibrate Drugs Market 3.4. Geographical Snapshot of the Fibrate Drugs Market, By Manufacturer share 4. Global Fibrate Drugss Market Overview, 2022-2029 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porters Five Forces Analysis 4.1.6.1. Threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. Threat of Substitute Products 4.1.6.5. Intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Global Fibrate Drugss Market 5. Supply Side and Demand Side Indicators 6. Global Fibrate Drugss Market Analysis and Forecast, 2022-2029 6.1. Global Fibrate Drugss Market Size & Y-o-Y Growth Analysis. 7. Global Fibrate Drugss Market Analysis and Forecasts, 2022-2029 7.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 7.1.1. Clofibrate 7.1.2. Fenofibrates 7.1.3. Fenofibric Acids 7.1.4. Gemfibrozil 7.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 7.2.1. Hospitals Pharmacies 7.2.2. Retail Pharmacies 7.2.3. Online Pharmacies 8. Global Fibrate Drugss Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2022-2029 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. North America Fibrate Drugs Market Analysis and Forecasts, 2022-2029 9.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 9.1.1. Clofibrate 9.1.2. Fenofibrates 9.1.3. Fenofibric Acids 9.1.4. Gemfibrozil 9.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 9.2.1. Hospitals Pharmacies 9.2.2. Retail Pharmacies 9.2.3. Online Pharmacies 10. North America Fibrate Drugs Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Fibrate Drugs Market Analysis and Forecasts, 2022-2029 11.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 11.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 12. Canada Fibrate Drugs Market Analysis and Forecasts, 2022-2029 12.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 12.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 13. Mexico Fibrate Drugs Market Analysis and Forecasts, 2022-2029 13.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 13.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 14. Europe Fibrate Drugs Market Analysis and Forecasts, 2022-2029 14.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 14.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 15. Europe Fibrate Drugs Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K. Fibrate Drugs Market Analysis and Forecasts, 2022-2029 16.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 16.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 17. France Fibrate Drugs Market Analysis and Forecasts, 2022-2029 17.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 17.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 18. Germany Fibrate Drugs Market Analysis and Forecasts, 2022-2029 18.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 18.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 19. Italy Fibrate Drugs Market Analysis and Forecasts, 2022-2029 19.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 19.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 20. Spain Fibrate Drugs Market Analysis and Forecasts, 2022-2029 20.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 20.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 21. Sweden Fibrate Drugs Market Analysis and Forecasts, 2022-2029 21.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 21.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 22. CIS Countries Fibrate Drugs Market Analysis and Forecasts, 2022-2029 22.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 22.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 23. Rest of Europe Fibrate Drugs Market Analysis and Forecasts, 2022-2029 23.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 23.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 24. Asia Pacific Fibrate Drugs Market Analysis and Forecasts, 2022-2029 24.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 24.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 25. Asia Pacific Fibrate Drugs Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Fibrate Drugs Market Analysis and Forecasts, 2022-2029 26.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 26.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 27. India Fibrate Drugs Market Analysis and Forecasts, 2022-2029 27.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 27.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 28. Japan Fibrate Drugs Market Analysis and Forecasts, 2022-2029 28.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 28.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 29. South Korea Fibrate Drugs Market Analysis and Forecasts, 2022-2029 29.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 29.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 30. Australia Fibrate Drugs Market Analysis and Forecasts, 2022-2029 30.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 30.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 31. ASEAN Fibrate Drugs Market Analysis and Forecasts, 2022-2029 31.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 31.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 32. Rest of Asia Pacific Fibrate Drugs Market Analysis and Forecasts, 2022-2029 32.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 32.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 33. Middle East Africa Fibrate Drugs Market Analysis and Forecasts, 2022-2029 33.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 33.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 34. Middle East Africa Fibrate Drugs Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2022-2029 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Fibrate Drugs Market Analysis and Forecasts, 2022-2029 35.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 35.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 36. GCC Countries Fibrate Drugs Market Analysis and Forecasts, 2022-2029 36.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 36.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 37. Egypt Fibrate Drugs Market Analysis and Forecasts, 2022-2029 37.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 37.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 38. Nigeria Fibrate Drugs Market Analysis and Forecasts, 2022-2029 38.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 38.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 39. Rest of ME&A Fibrate Drugs Market Analysis and Forecasts, 2022-2029 39.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 39.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 40. South America Fibrate Drugs Market Analysis and Forecasts, 2022-2029 40.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 40.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 41. South America Fibrate Drugs Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2022-2029 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Fibrate Drugs Market Analysis and Forecasts, 2022-2029 42.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 42.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 43. Argentina Fibrate Drugs Market Analysis and Forecasts, 2022-2029 43.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 43.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 44. Rest of South America Fibrate Drugs Market Analysis and Forecasts, 2022-2029 44.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 44.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Global Fibrate Drugss Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Applications and R&D Investment 45.2.2. New Product Launches and Product Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements 45.3. Company Profile : Key Players 45.3.1. Teva Pharmaceutical Industries 45.3.1.1. Company Overview 45.3.1.2. Financial Overview 45.3.1.3. Geographic Footprint 45.3.1.4. Product Portfolio 45.3.1.5. Business Strategy 45.3.1.6. Recent Developments 45.3.2. Pfizer Inc. 45.3.3. Mylan N.V. 45.3.4. Sanofi SA 45.3.5. Novartis AG 45.3.6. GlaxoSmithKline plc 45.3.7. Sun Pharmaceutical Industries, Inc. 45.3.8. Macleods Pharmaceuticals Limited 45.3.9. Aurobindo Pharma 45.3.10. Abbott 45.3.11. Lupin 45.3.12. Zydus Candila 45.3.13. Hetero Drugs 45.3.14. Dr. Reddy’s Laboratories 45.3.15. Torrent Pharmaceuticals 46. Primary Key Insights